Browsing Medicina Preventiva y Salud Pública by Subject "Biosimilar agent"
Now showing items 1-1 of 1
-
Article
Switching from reference infliximab to CT-P13 in patients with inflammatory bowel disease: results of a multicenter study after 12 months
(Aran Ediciones S.A., 2018)Background and aims: infliximab has changed the natural history of inflammatory bowel disease (IBD). The advent of ...